Buy Syngene International, target price Rs 985: IIFL Securities

IIFL Securities issued a buy call on Syngene International on December 2, recommending investors to purchase the stock. The target price was set at Rs 985, indicating a potential upside of 3.68% from the current market price of Rs 950. This recommendation signals the brokerage firm's positive outlook on the company's growth prospects and financial performance.

About Syngene International:

Syngene International Ltd., a Biocon Group company, is a leading contract research, development, and manufacturing organization (CRDMO), providing innovative end-to-end solutions to the pharmaceutical, biotechnology, and healthcare industries worldwide. Headquartered in Bengaluru, India, Syngene offers a comprehensive portfolio of discovery, development, and manufacturing services, including preclinical, clinical development, and cGMP manufacturing. With a global footprint and state-of-the-art facilities, Syngene has a proven track record of successfully collaborating with global partners to deliver innovative therapies that improve patient lives. The company's strong scientific foundation, experienced team, and commitment to quality make it a trusted partner for clients seeking to accelerate their R&D efforts.

52 Week Price Trend:

Syngene International (NSE:SYNGENE) has witnessed a significant surge in its share price, rising from Rs 567.5 to the current market price of Rs 950. This remarkable growth of 67.3% over the last 52 weeks reflects the company's strong fundamentals and the robust growth prospects in the pharmaceutical and biotechnology sectors. Syngene's focus on contract research and manufacturing services has positioned it as a key player in the industry, and the increasing demand for its services has contributed to its impressive performance. The company's strong order book, strategic acquisitions, and expansion plans further support its growth trajectory, making it an attractive investment option for long-term investors.

Stratzy's MOST Analysis:

Stratzy's MOST Framework has evaluated SYNGENE with an exceptional AAA rating. This comprehensive assessment considers four key pillars: Management, Outlook, Safety, and Trend. By scoring each pillar, Stratzy assigns an overall rating, indicating the company's fundamental risk profile. SYNGENE's AAA rating under this framework suggests that it possesses strong management, a positive outlook, robust financial safety, and a favorable market trend. This indicates a low fundamental risk profile and makes SYNGENE a potentially attractive investment opportunity.

Company's Fundamentals:

Syngene International, listed on the National Stock Exchange (NSE), has a current stock PE ratio of 57.74, indicating that investors are willing to pay 57.74 times the company's annual earnings per share for each share of its stock. The Price-to-Book (PB) ratio of 7.55 suggests that the market value of Syngene International's assets is 7.55 times its book value. Lastly, the dividend yield of 0.07% implies that for every 100 rupees invested in Syngene International, investors can expect to receive a dividend of only 0.07 rupees annually.

Fundamental and Technical information provided in this blog were last updated on 30 Nov, 2024

Disclaimer: The information and recommendations presented in this section, including any attached reports, are sourced from third-party providers through diverse channels. The views and opinions expressed within these materials belong solely to their respective creators. These views and opinions do not necessarily reflect the position of Stratzy Fintech Pvt Ltd. Stratzy explicitly disclaims any guarantees, express or implied, regarding the accuracy and reliability of the provided content. We strongly advise consulting with a licensed financial advisor before making any investment decisions based on this information. Remember, seeking independent financial advice is crucial.